Cipla said it expects its US business to build momentum over FY27, even after a weak June quarter weighed on earnings. The drugmaker maintained its full-year outlook, indicating confidence that performance will improve as the year progresses.
The company’s profit fell 39% in the June quarter, with softer US sales acting as the main drag on results. Even so, Cipla expects sequential improvement in the US market, suggesting that the first quarter may not reflect the trend it sees for the rest of the fiscal year.
Cipla has kept its full-year Ebitda margin guidance at 18.5% to 20%. It also expects US sales to reach a run rate of about $1 billion by the end of the fiscal period, supported by key product launches planned during the year.
The update points to a strategy centered on new launches and a stronger US sales trajectory after a slow start. For the market, the focus is likely to remain on how quickly Cipla converts those launches into revenue and whether quarterly improvement is strong enough to support its guidance.
